1174P The MET inhibitor ABN401 in combination with the third-generation EGFR-TKI is effective MET-amplified and EGFR-mutant NSCLC with acquired resistance to third-generation EGFR-TKI in preclinical models

Abstract

ABN401 is a highly selective MET kinase inhibitor, demonstrates a safety profile in the clinical study, and remarkably inhibits tumor cell harboring MET alterations. MET gene amplification is the most frequent cause of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients. Combining therapy of MET-TKI and EGFR-TKI has emerged as a promising therapeutic strategy to overcome EGFR-TKI resistance, but its mechanism and efficacy remain controversial.